{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FAST+alone&page=3", "query": { "intervention": "FAST alone", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 1359, "total_pages": 136, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FAST+alone&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FAST+alone&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T21:41:28.818Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01068743", "title": "Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "saxagliptin", "type": "DRUG" }, { "name": "metformin", "type": "DRUG" }, { "name": "saxagliptin + metformin (FDC tablet)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 24, "start_date": "2010-02", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2015-05-08", "last_synced_at": "2026-10-22T21:41:28.818Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01068743" }, { "nct_id": "NCT07560150", "title": "Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Pharmacokinetics", "Pharmacodynamics", "Insulin Aspart" ], "interventions": [ { "name": "I004", "type": "DRUG" }, { "name": "NovoLog", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amphastar Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 62, "start_date": "2026-04-06", "completion_date": "2026-06-25", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-22T21:41:28.818Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07560150" }, { "nct_id": "NCT01779869", "title": "Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Ischemic Heart Disease" ], "interventions": [ { "name": "Regadenoson", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2013-01", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2018-06-15", "last_synced_at": "2026-10-22T21:41:28.818Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01779869" }, { "nct_id": "NCT00989586", "title": "Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "milatuzumab", "type": "BIOLOGICAL" }, { "name": "veltuzumab", "type": "BIOLOGICAL" }, { "name": "Correlative/Special Studies", "type": "PROCEDURE" }, { "name": "Quantitative T-, B-, and NK cell subsets", "type": "PROCEDURE" }, { "name": "Pharmacokinetics", "type": "PROCEDURE" }, { "name": "Human Anti-Human Antibodies", "type": "PROCEDURE" }, { "name": "veltuzumab and milatuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Beth Christian", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2009-09", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-02-06", "last_synced_at": "2026-10-22T21:41:28.818Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00989586" }, { "nct_id": "NCT00246571", "title": "Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "SU011248", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 217, "start_date": "2006-01", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2012-07-12", "last_synced_at": "2026-10-22T21:41:28.818Z", "location_count": 77, "location_summary": "Corona, California • Fullerton, California • Glendora, California + 59 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Glendora", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00246571" }, { "nct_id": "NCT03464019", "title": "Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Paroxysmal Supraventricular Tachycardia" ], "interventions": [ { "name": "Etripamil", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Etripamil Test Dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Milestone Pharmaceuticals Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1097, "start_date": "2018-06-18", "completion_date": "2023-01-20", "has_results": true, "last_update_posted_date": "2024-07-12", "last_synced_at": "2026-10-22T21:41:28.818Z", "location_count": 54, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 44 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03464019" }, { "nct_id": "NCT07290439", "title": "Improving Maternal and Child Health Through Point-of-care STI Testing", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Treponema Pallidum Infection", "Chlamydia Trachomatis Infection", "Neisseria Gonorrheae Infection", "Trichomonas Vaginalis Vaginitis", "Sexually Transmitted Infection" ], "interventions": [ { "name": "Point-of-care STI tests", "type": "DIAGNOSTIC_TEST" }, { "name": "Standard of care STI testing", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 756, "start_date": "2026-08-11", "completion_date": "2030-06", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-22T21:41:28.818Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07290439" }, { "nct_id": "NCT06643728", "title": "A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity", "Overweight" ], "interventions": [ { "name": "Bimagrumab", "type": "DRUG" }, { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Bimagrumab Placebo", "type": "DRUG" }, { "name": "Tirzepatide Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 252, "start_date": "2024-10-21", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-10-22T21:41:28.818Z", "location_count": 12, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Walnut Creek, California + 9 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Lake Worth", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06643728" }, { "nct_id": "NCT05431153", "title": "A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Single dose of PF-07104091 as Tablet Formulation A (Treatment A)", "type": "DRUG" }, { "name": "Single dose of PF-07104091 as Tablet Formulation B (Treatment B)", "type": "DRUG" }, { "name": "Single dose of PF-07104091 as Tablet Formulation C (Treatment C)", "type": "DRUG" }, { "name": "Single dose of PF-07104091 as Tablet Formulation D (Treatment D)", "type": "DRUG" }, { "name": "Single dose of PF-07104091 as Tablet Formulation C (Treatment E)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "MALE", "summary": "18 Years to 60 Years · Male only" }, "enrollment_count": 30, "start_date": "2022-06-10", "completion_date": "2022-10-17", "has_results": true, "last_update_posted_date": "2024-04-08", "last_synced_at": "2026-10-22T21:41:28.818Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05431153" }, { "nct_id": "NCT00602407", "title": "Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Intermittent Claudication" ], "interventions": [ { "name": "Cilostazol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roxane Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 36, "start_date": "2004-02", "completion_date": "2004-03", "has_results": false, "last_update_posted_date": "2018-01-23", "last_synced_at": "2026-10-22T21:41:28.818Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00602407" } ] }